We recently demonstrated in a multicenter, randomized controlled trial that treatment with the prolactin release inhibitor bromocriptine in addition to guideline-recommended heart failure therapy is safe and improves LV function and clinical outcome in PPCM [10]. The gene discussed is PRL; the disease is heart failure.